Exogenous surfactant therapy for premature infants with respiratory distress syndrome has had a significant impact on infant mortality and on some complications of prematurity.
Yet the total number of low-birthweight infants has not declined, resulting in a high-risk population who would require surfactant therapy and long-term child care.
Surviving low-weight infants (despite surfactant therapy) remain at risk for the consequences of premature birth, such as neurosensory impairment, cerebral palsy, and chronic lung disease.
In addition, because of the close association between poverty and low birthweight, surviving premature infants are at increased risk for the new morbidities such as violence, homelenessness, child abuse and neglect, and additive drug use.
A goal should be to reduce the risk of being born with a low birthweight, rather than having to treat the consequences of premature gestation.
Despite the marvelous advances that permit us to treat respiratory distress syndrome, the continuing high low-birthweight rate places a significant strain on our health care system.
The goal should be redirected to identifying large population-based efforts to reduce the number based efforts to reduce the number of low-birthweight infants.
Mots-clés Pascal : Détresse respiratoire, Nourrisson, Homme, Poids naissance faible, Complication, Surfactant pulmonaire, Traitement, Survie, Statut socioéconomique, Politique sanitaire, Etats Unis, Amérique du Nord, Amérique, Appareil respiratoire pathologie, Gestation pathologie, Prématurité, Nouveau né pathologie
Mots-clés Pascal anglais : Respiratory distress, Infant, Human, Low birth weight, Complication, Pulmonary surfactant, Treatment, Survival, Socioeconomic status, Health policy, United States, North America, America, Respiratory disease, Pregnancy disorders, Prematurity, Newborn diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0437201
Code Inist : 002B11D. Création : 01/03/1996.